Nuklearmedizin - NuclearMedicine, Inhaltsverzeichnis

Nuklearmedizin
DOI: 10.1055/a-2438-7278

Original Article

Comparison of whole-body ¹⁸F-FDG-PET/CT with ¹⁸F-FDG-PET/CT limited to skull base to upper abdomen for primary staging of lung cancer – a retrospective explorative analysis

Vergleich der Ganzkörper-FDG-PET/CT-Methode mit einer auf Schädelbasis bis Oberbauch beschränkten FDG-PET/CT zum Primärstaging von Lungenkarzinomen – eine retrospektive explorative Analyse

Lukas Schulz

¹2. Medizinische Abteilung mit Pneumologie und Karl-Landsteiner Institut für Lungenforschung und pneumologische Onkologie, Wiener Gesundheitsverbund Klinik Ottakring, Wien, Austria (Ringgold ID: RIN643471)

,

Georg-Christian Funk

¹2. Medizinische Abteilung mit Pneumologie und Karl-Landsteiner Institut für Lungenforschung und pneumologische Onkologie, Wiener Gesundheitsverbund Klinik Ottakring, Wien, Austria (Ringgold ID: RIN643471)

,

Klaus Kirchbacher

¹2. Medizinische Abteilung mit Pneumologie und Karl-Landsteiner Institut für Lungenforschung und pneumologische Onkologie, Wiener Gesundheitsverbund Klinik Ottakring, Wien, Austria (Ringgold ID: RIN643471)

,

Elena Egger

¹2. Medizinische Abteilung mit Pneumologie und Karl-Landsteiner Institut für Lungenforschung und pneumologische Onkologie, Wiener Gesundheitsverbund Klinik Ottakring, Wien, Austria (Ringgold ID: RIN643471)

,

Nino Müser

¹2. Medizinische Abteilung mit Pneumologie und Karl-Landsteiner Institut für Lungenforschung und pneumologische Onkologie, Wiener Gesundheitsverbund Klinik Ottakring, Wien, Austria (Ringgold ID: RIN643471)

,

Siroos Mirzaei

²Institut für Nuklearmedizin mit PET-Zentrum, Wiener Gesundheitsverbund Klinik Ottakring, Wien, Austria (Ringgold ID: RIN643471)

› Institutsangaben

Abstract

Aim

The gold standard for ruling out distant metastases as part of primary staging in lung cancer is whole-body ¹⁸F-FDG-PET/CT, but this method is resource-intensive. Recent evidence suggests that examining only the thorax and upper abdomen may be sufficient [1] [2] [3]. If a limited ¹⁸F-FDG-PET/CT approach proves effective for proper staging, it could lead to quicker examinations and reduced radiation exposure. This study aimed to determine whether limited ¹⁸F-FDG-PET/CT is adequate for the primary staging of lung cancer.

Methods

In this study, a retrospective analysis of 161 patients (87 men, 74 women; age range 31–88 y) with recent or suspected lung cancer who had undergone a whole-body ¹⁸F-FDG-PET/CT examination for primary staging at our clinic between 2018 and 2022 was conducted. None of these patients showed evidence of extrathoracic metastases before the ¹⁸F-FDG-PET/CT examination. The images were divided into three regions: “head-neck” (HN), “thorax-upper abdomen” (TUA), and “lower abdomen-hip” (LAH). TNM staging based on the HN plus TUA region was compared with TNM staging based on the whole body.

Results

Among the 161 subjects, 7 (4%) showed malignancy-suspect lesions in HN, 110 (68%) in TUA and 7 (4%) had suspected distant metastases in LAH. The TNM staging based on HN plus TUA corresponded to TNM staging based on the whole body in 161 (100%) examinations. This finding aligns with similar results in previous literature.

Conclusion

¹⁸F-FDG-PET/CT limited to HN and TUA yielded accurate staging in all cases. Adopting this method could facilitate the examination and correct staging of more individuals, reducing exam waiting times and physician reporting time and minimising radiation exposure.

Keywords

Keywords

lung cancer - primary staging - limited field of view

Literature
1 Arens AI, Postema JW, Schreurs WM. et al. FDG-PET/CT Limited to the Thorax and Upper Abdomen for Staging and Management of Lung Cancer. PLoS One 2016; 11: e0160539
2 Aquino SL, Fischman AJ. Does whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography have an advantage over thoracic positron emission tomography for staging patients with lung cancer?. Chest 2004; 126: 755-760
3 Sebro R, Mari-Aparici C, Hernandez-Pampaloni M. Value of true whole-body FDG-PET/CT scanning protocol in oncology: optimization of its use based on primary diagnosis. Acta Radiol 2013; 54: 534-539
4 Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin e.V. (DGP), Deutsche Krebsgesellschaft e.V. S3-Leitlinie Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. Kapitel 6.3 Bildgebung und Diagnosesicherung. Version 2.1 2022:. In: . 87-98
5 Delgado Bolton RC, Calapaquí-Terán AK, Giammarile F. et al. Role of (18)F-FDG PET/CT in establishing new clinical and therapeutic modalities in lung cancer. A short review. Rev Esp Med Nucl Imagen Mol (Engl Ed) 2019; 38: 229-233
6 Farsad M. FDG PET/CT in the Staging of Lung Cancer. Curr Radiopharm 2020; 13: 195-203
7 National Center for Biotechnology Information. PubChem Compound Summary for CID 68614, Fludeoxyglucose F-18. 2024 Zugriff am 15. April 2024 unter: https://pubchem.ncbi.nlm.nih.gov/compound/Fludeoxyglucose-F-18
8 Viney RC, Boyer MJ, King MT. et al. Randomized controlled trial of the role of positron emission tomography in the management of stage I and II non-small-cell lung cancer. J Clin Oncol 2004; 22: 2357-2362
9 Verschakelen JA, Bogaert J, De Wever W. Computed tomography in staging for lung cancer. Eur Respir J Suppl 2002; 35: 40s-48s
10 Martí-Climent JM, Prieto E, Morán V. et al. Effective dose estimation for oncological and neurological PET/CT procedures. EJNMMI research 2017; 7: 37
11 Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987; 15: 657-680
12 Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 1998; 17: 873-890